Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

3,621 total articles

Coherent Director Executes $856,550 Share Sale Amid Company Momentum

Coherent Director Executes $856,550 Share Sale Amid Company Momentum

Stephen A. Skaggs, a director at Coherent Corp, disposed of 3,523 shares on March 9, 2026, through a pre-arranged Rule 10b5-1 plan, generating roughly $856,550. The transaction occurred at a weighted average price of $243.1309 per share, with sale prices between $237.90 and $250.00. After the sale Skaggs retains 16,864 shares. Coherent's stock has …

Joby Aviation President Disposes of $31,230 in Shares Amid Certification and Production Milestones

Joby Aviation President Disposes of $31,230 in Shares Amid Certification and Production Milestones

Didier Papadopoulos, Joby Aviation's President of Aircraft OEM, sold 3,087 shares of the company's common stock on March 10 and 11, 2026, for a combined total of $31,230. The transactions were reported on a Form 4 and included sales under a 10b5-1 plan. The moves come as Joby progresses flight testing of an FAA-spec aircraft designated N547JX, secu…

Aquestive Therapeutics CPO Executes Stock Sale to Satisfy Tax Withholding; Retains Substantial Equity Stake

Aquestive Therapeutics CPO Executes Stock Sale to Satisfy Tax Withholding; Retains Substantial Equity Stake

Summary: Aquestive Therapeutics Chief People Officer Peter E. Boyd completed a mandated sale of 29,814 common shares on March 10, 2026, while also taking delivery of restricted stock and stock options that vest over three years. The sale, executed under the companys equity incentive plan to meet tax withholding obligations, generated $124,413. Fol…

Aquestive CEO Disposes of $753,965 in Stock as Company Navigates Regulatory and Earnings Headwinds

Aquestive CEO Disposes of $753,965 in Stock as Company Navigates Regulatory and Earnings Headwinds

Aquestive Therapeutics President and CEO Daniel Barber sold 180,677 shares on March 10, 2026, realizing $753,965 at a weighted average price of $4.173. The Form 4 filing also shows acquisitions on March 9, 2026 of 262,000 common shares valued at $0 and 523,000 Non-Qualified Stock Options with a $4.29 exercise price. The insider transaction occurs a…

Aquestive Chief Legal Officer Disposes of $167K in Stock While Receiving Restricted Shares and Options

Aquestive Chief Legal Officer Disposes of $167K in Stock While Receiving Restricted Shares and Options

Aquestive Therapeutics executive transactions filed with the SEC show Chief Legal Officer Lori J. Braender sold roughly $167,345 of common stock on March 10, 2026, while the prior day she received restricted shares and non-qualified options. The company reported a larger-than-expected fourth-quarter 2025 loss and is pursuing an NDA re-submission fo…

National Presto Director Sells $347,975 in Stock Under 10b5-1 Plan

National Presto Director Sells $347,975 in Stock Under 10b5-1 Plan

National Presto Industries director Randy F. Lieble sold 2,417 shares of the company's common stock on March 11, 2026 at $143.97 per share, bringing the total transaction value to $347,975. The trade was carried out under a Rule 10b5-1 trading plan adopted November 10, 2025. Following the sale, Lieble holds 5,222 shares directly and additionally ha…

Woodward CEO Charles Blankenship Sells $2.85M in Stock, Exercises Options as Company Pursues Aerospace Acquisition

Woodward CEO Charles Blankenship Sells $2.85M in Stock, Exercises Options as Company Pursues Aerospace Acquisition

Woodward, Inc. Chairman and CEO Charles P. Blankenship sold common shares on March 9 and 10, 2026, for roughly $2.85 million under a pre-arranged Rule 10b5-1 plan and exercised options to acquire additional shares. The moves coincide with the company trading close to its 52-week high, an announced acquisition aimed at strengthening its aerospace co…

Vicor Chairman Sells $8.8M in Stock Under 10b5-1 Plan

Vicor Chairman Sells $8.8M in Stock Under 10b5-1 Plan

Vicor Corp Chairman and CEO Patrizio Vinciarelli sold 43,678 shares of common stock on March 10, 2026, in transactions executed under a Rule 10b5-1 plan adopted November 3, 2025. The sales, completed at weighted-average prices between $169.70 and $182.1746, generated roughly $8.8 million in proceeds. Following the trades, Vinciarelli directly holds…

Vicor Chairman Executes $8.21M Share Sale Under 10b5-1 Plan

Vicor Chairman Executes $8.21M Share Sale Under 10b5-1 Plan

Vicor Corp Chairman and CEO Patrizio Vinciarelli sold 49,990 shares of common stock on March 9, 2026, through several transactions priced between $159.2269 and $170.023, generating $8,212,934 in proceeds. The trades were carried out under a Rule 10b5-1 plan adopted November 3, 2025. After the dispositions, Vinciarelli directly holds 9,519,813 share…

Rambus General Counsel Disposes $404,007 in Shares Under 10b5-1 Plan

Rambus General Counsel Disposes $404,007 in Shares Under 10b5-1 Plan

Rambus Inc. (RMBS) disclosed that Senior Vice President and General Counsel John Shinn sold 4,556 shares on March 10, 2026, for a total of $404,007 under a pre-arranged Rule 10b5-1 plan. The transactions, reported on a Form 4, leave Shinn with 18,467 shares. The company recently reported fourth-quarter 2025 results roughly in line with expectations…

Gaia Director Increases Stake with $31,618 Purchase

Gaia Director Increases Stake with $31,618 Purchase

Paul Howard Sutherland, a director of GAIA, INC (NASDAQ:GAIA), bought 10,250 Class A Common Stock shares on March 10, 2026, for $3.0847 per share, a transaction totaling $31,618. After the purchase Sutherland directly owns 295,457 shares. Analysts cited by InvestingPro place GAIA price targets between $6 and $10 and note an 87% gross profit margin …